Can treating depression reduce mortality after an acute myocardial infarction?

Psychosomatic Medicine

Volumn 61, Issue 5, 1999, Pages 666-675

  Carney, Robert M ^a   Freedland, Kenneth E ^a   Veith, Richard C ^b   Jaffe, Allan S ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Coronary heart disease; Depression; Mortality

Indexed keywords

SERTRALINE;

ACUTE HEART INFARCTION; ARTICLE; DEPRESSION; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE;

EID: 0032883976     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006842-199909000-00009     Document Type: Article

References (97)

1. Carney RM, Rich MW, Freedland KE, teVelde A, Saini J, Simeone C, Clark K. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988;50:627-33.
2. Barefoot JC, Helms MJ, Mark DB, Blumenthal JA, Califf RM, Haney TL, O'Connor CM, Siegler IC, Williams RB. Depression and long-term mortality risk in patients with coronary artery disease. Am J Cardiol 1996;78:613-7.
3. Ahern DK, Gorkin L, Anderson JL, Tierney C, Ewart C, Capone RJ, Schron E, Kornfeld D, Herd JA, Richardson DW, Follick MJ. Biobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS). Am J Cardiol 1990;66: 59-62.
4. Frasure-Smith N, Lespèrance F, Talajic M. Depression following myocardial infarction: impact on 6 month survival. JAMA 1993; 270:1819-25.
5. Frasure-Smith N, Lespèrance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91:999-1005.
6. Ladwig KH, Kieser M, Konig J, Breithardt G, Borggrefe M. Affective disorders and survival after acute myocardial infarction. Eur Heart J 1991;12:959-64.
7. Silverstone PH. Depression and outcome in acute myocardial infarction. BMJ 1987;294:219-20.
8. Schleifer SJ, Macari-Hinson MM, Coyle DA, Slater WR, Kahn M, Gorlin R, Zucker HD. The nature and course of depression following myocardial infarction. Arch Intern Med 1988;149: 1785-9.
9. Carney RM; Freedland KE, Jaffe AS. Insomnia and depression before myocardial infarction. Psychosom Med 1990;52:603-9.
10. Lesperance F, Frasure-Smith N, Taljic M. Major depression before and after myocardial infarction: its nature and consequences. Psychosom Med 1996;58:99-110.
11. American Heart Association. Heart and stroke facts: 1995 statistical supplement. Dallas: American Heart Association; 1995.
12. Avery D, Winokur G. Mortality in depressed patients treated with electroconvulsive therapy and antidepressants. Arch Gen Psychiatry 1976;33:1029-37.
13. Shores MM, Pasualy M, Veith RC. Major depression and heart disease: treatment trials. Semin Clin Neuropsychiatry 1998;3: 87-101.
14. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992;149: 999-1010.
15. McGovern PG, Pankow JS, Shahar E, Dolisznky KM, Folsom AR, Blackburn H, Luepker RV, for the Minnesota Heart Survey Investigators. Recent trends in acute coronary heart disease mortality, morbidity, medical care, and risk factors. N Eng J Med 1996;334:884-90.
16. Veith RC, Raskind MA, Caldwell JH, et al. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. N Engl J Med 1982;306:954-9.
17. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG, Gaffney A, Narayam M, Finkel MS, McCafferty J, Gergel I. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279: 287-91.
18. Pary RP, Tobias CR, Lippmann S. Antidepressants and the cardiac patient: selecting an appropriate medication. Postgrad Med 1989;85:267-9.
19. Glassman AH, Roose SP, Bigger JT. The safety of tricyclic antidepressants in cardiac patients: risk/benefit reconsidered. JAMA 1993;269:2673-5.
20. Warrington SJ, Padgham C, Lader M. The cardiovascular effects of antidepressants. Psychol Med Monogr Suppl 1989;16:1-40.
21. Cardiac Arrhythmia Suppression Trial Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
22. Roose SP, Dalack GW, Classman AH, Woodring S, Walsh T, Giardina WGV. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991;148: 512-6.
23. Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 1995;56:574-9.
24. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153: 311-20.
25. Sheline Y, Freedland KE, Carney RM. How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Am J Med 1997;102:54-9.
26. Carney RM, Freedland KE, Sheline Y, Weiss E. Depression and coronary heart disease: a review for cardiologists. Clin Cardiol 1997;20:196-200.
27. Rice EH, Sombrotto LB, Markowitz JC. Cardiovascular morbidity in high-risk patients during ETC. Am J Psychiatry 1994;151: 1637-41.
28. Zielinski RJ, Roose SP, Devanand DP. Cardiovascular complications of ECT in depressed patients with cardiac disease. Am J Psychiatry 1993;150:904-9.
29. Carney RM, Freedland KE, Rich MW, Jaffe AS. Depression as a risk factor for cardiac events in established coronary heart disease: a review of possible mechanisms. Ann Behav Med 1995;17:142-9.
30. Glassman AH, Heizer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, Johnson J. Smoking, smoking cessation, and major depression. JAMA 1990;264:1546-9.
31. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren CA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986;143:993-7.
32. Wells KB, Golding JM, Burnam MA. Affective, substance use, and anxiety disorders in persons with arthritis, diabetes, heart disease, high blood pressure, or chronic lung conditions. Gen Hosp Psychiatry 1989;1:320-7.
33. Pfohl B, Rederer M, Coryell W, Stangl D. Association between post dexamethasone cortisol level and blood pressure in depressed inpatients. J Nerv Ment Dis 1991;179:44-7.
34. Oxenkrug GF, Branconnier RJ, Harto-Truax N, Cole JO. Is serum cholesterol a biological marker for major depressive disorder? Am J Psychiatry 1983;40:920-1.
35. Anda R, Williamson D, Jones D, Macera C, Eaker E, Glassman A, Marks J. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of US adults. Epidemiology 1993;4: 285-94.
36. Guiry E, Conroy RM, Hickey N, Mulcahy R. Psychological response to an acute coronary event and its effect on subsequent rehabilitation and lifestyle change. Clin Cardiol 1987;10: 256-60.
37. Carney RM, Freedland KE, Eisen S, Rich MW, Jaffe AS. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol 1995;14:88-90.
38. Cameron O. Depression increases post-MI mortality. How? [editorial comment]. Psychosom Med 1996;58:111-2.
39. Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998;155:4-11.
40. Esler M, Turbott J, Schwarz R, Leonard P, Bobik A, Skews H, Jackman G. The peripheral kinetics of norepinephrine in depressive illness. Arch Gen Psychiatry 1982;39:285-300.
41. Lake CR, Pickar D, Ziegler MG, Lipper S, Slater S, Murphy DL. High plasma NE levels in patients with major affective disorder. Am J Psychiatry 1982;139:1315-8.
42. Roy A, Pickar D, De Jong J, Karoum F, Linnoila M. NE and its metabolites in cerebrospinal fluid, plasma, and urine. Arch Gen Psychiatry 1988;45:849-57.
43. Siever L, Davis K. Overview: toward a dysregulation hypothesis of depression. Am J Psychiatry 1985;142:1017-31.
44. Veith RC, Lewis N, Linares OA, Barnes RF, Raskind MA, Villacres EC, Murburg MM, Ashleigh EA, Castillo S, Peskind ER, Pascualy M, Halter JB. Sympathetic nervous system activity in major depression. Arch Gen Psychiatry 1994;51:411-22.
45. Wyatt RJ, Portnoy B, Kupfer DJ, Snyder F, Engelman K. Resting plasma catecholamine concentrations in patients with depression and anxiety. Arch Gen Psychiatry 1971;24:65-70.
46. Dawson ME, Schell AM, Catania JJ. Autonomic correlates of depression and clinical improvement following electroconvulsive shock therapy. Psychophysiology 1977;14:569-78.
47. Lahmeyer HW, Bellier SN. Cardiac regulation and depression. Psychiatr Res 1987;21:1-6.
48. Dallack GW, Roose SP. Perspectives on the relationship between cardiovascular disease and affective disorder. J Clin Psychiatry 1990;51(Suppl):4-9.
49. Imaoka K, Inoue H, Inoue Y, Hazama H, Tanaka T, Yamane N. R-R intervals of ECG in depression. Folia Psychiatr Neurol Jpn 1985;39:485-7.
50. Rechlin T. Are affective disorders associated with alterations of heart rate variability? J Affect Disord 1994;32:271-5.
51. Kliks BR, Burgess MJ, Abildskov JA. Influence of sympathetic tone on ventricular fibrillation threshold during experimental coronary occlusion. Am J Cardiol 1975;36:45-9.
52. Podrid PJ, Fuchs T, Candinas R. Role of the sympathetic nervous system in the genesis of ventricular arrhythmia. Circulation 1990;82(Suppl 1):103-10.
53. Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 1991;325: 618-24.
54. Schwartz PJ, Stone HL. Left stellectomy in the prevention of ventricular fibrillation caused by acute myocardial ischemia in conscious dogs with anterior myocardial infarction. Circulation 1980;62:1256-65.
55. Verrier RL, Thompson PL, Lown B. Ventricular vulnerability during sympathetic stimulation: role of heart rate and blood pressure. Cardiovasc Res 1974;8:602-10.
56. Carney RM, Freedland KE, Rich MW, Smith LJ, Jaffe AS. Ventricular tachycardia and psychiatric depression in patients with coronary artery disease. Am J Med 1993;95:23-8.
57. Kennedy GJ, Hofer MA, Cohen D, Shindledecker MA, Fisher JD. Significance of depression and cognitive impairment in patients undergoing programed stimulation of cardiac arrhythmias. Psychosom Med 1987;49:410-21.
58. Flory JD, Mann JJ, Manuck SB, Muldoon MF. Recovery from major depression is not associated with normalization of serotonergic function. Biol Psychiatry 1998;43:320-6.
59. Gurguis GNM, Meador-Woodruff JH, Haskett RF, Greden JF. Multiplicity of depressive episodes: phenomenological and neuroendocrine correlates Biol Psychiatry 1990;27:1156-64.
60. Jarrett DB, Miewald JM, Kupfer DJ. Recurrent depression is associated with a persistent reduction in sleep related growth hormone secretion. Arch Gen Psychiatry 1990;47:113-8.
61. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Med Sci 1996;93:3908-13.
62. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation 1996;93:1043-65.
63. Kleiger RE, Miller JP, Bigger JT, Moss AJ. Decreased heart rate variability and its association with mortality after myocardial infarction. Am J Cardiol 1987;113:256-62.
64. Rich MW, Saini JS, Kleiger RE, Carney RM, teVelde A, Freedland KE. Correlation of heart rate variability with clinical and angiographic variables and late mortality after coronary angiog-raphy. Am J Cardiol 1988;62:714-7.
65. Frey B, Binder T, Teufelsbauer H. Heart rate variability and patient outcome in advanced heart failure. J Am Coll Cardiol 1993;21(Suppl A):286A.
66. Carney RM, Freedland KE, Veith RC, Cryer PE, Skala JA, Lynch T, Jaffe AS. Major depression, heart rate, and plasma norepinephrine in patients with coronary heart disease. Biol Psychiatry 1999;45:458-63.
67. Carney RM, Rich MW, teVelde A, Saini J, Clark K, Freedland KE. Heart rate, heart rate variability and depression in patients with coronary artery disease. J Psychosom Res 1988;32:159-64.
68. Carney RM, Saunders RD, Freedland KE, Stein P, Rich MW, Jaffe AS. Depression is associated with reduced heart rate variability in patients with coronary heart disease. Am J Cardiol 1995;76: 562-4.
69. Rechlin T. Decreased parameters of heart rate variation in amitriptyline treated patients: lower parameters in melancholic depression than in neurotic depression - a biological marker? Biol Psychiatry 1994;36:705-7.
70. Schultz SK, Anderson EA, van de Borne P. Heart rate variability before and after treatment with electroconvulsive therapy. J Affect Disord 1997;44:13-20.
71. Jakobsen J, Hauksson P, Vestergaard P. Heart rate variation in patients treated with antidepressants: an index of anticholinergic effects? Psychopharmacology 1984;84:544-8.
72. Rechlin T, Claus D, Weis M, Kaschka WP. Decreased heart rate variability parameters in amitriptyline treated depressed patients: biological and clinical significance. Eur Psychiatry 1995;10:189-94.
73. Yeragani VK, Pohl R, Balon R, Ramesh C, Glitz D, Weinberg P, Merlos B. Effect of imipramine treatment on heart rate variability measures. Neuropsychobiology 1992;26:27-32.
74. Rechlin T, Weis M, Claus D. Heart rate variability in depressed patients and differential effects of paroxetine and amitriptyline on cardiovascular autonomic functions. Pharmacopsychiatry 1994;27:124-8.
75. Balogh S, Fitzpatrick DF, Hendricks SE, Paige SR. Increases in heart rate variability with successful treatment in patients with major depressive disorder. Psychopharmacol Bull 1993;29: 201-6.
76. Khaykin Y, Dorian P, Baker B, Shapiro C, Sandor P, Mironov D, Irvine J, Newman D. Autonomic correlates of antidepressant treatment using heart-rate variability analysis. Can J Psychiatry 1998;43:183-6.
77. Sandrone G, Mortara A, Torzillo D, LaRovere A, Malliani A, I Lombardi F. Effects of beta blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infarction. Am J Cardiol 1994;74:340-5.
78. Niemela MJ, Airaksinen KE, Huikuri HV. Effect of beta-blockade on heart rate variability in patients with coronary artery disease. J Am Coll Cardiol 1994;23:1370-7.
79. Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247:1707-14.
80. Stein PK, Rottman JN, Kleiger RE. Effect of 21 mg transdermal nicotine patches and smoking cessation on heart rate variability. Am J Cardiol 1996;77:701-5.
81. Herlitz J, Bengtson A, Hjalmarson A, Karlson BW. Smoking habits in consecutive patients with acute myocardial infarction: prognosis in relation to other risk indicators and to whether or not they quite smoking. Cardiology 1995;86:496-502.
82. Stein PK, Rottman JN, Kleiger RE, Ehsani AA. Exercise training increases heart rate variability in normal older adults. J Am Coll Cardiol 1996;27(Suppl A):146A.
83. Malfatto G, Facchini M, Bragato R, Branzi G, Sala L, Leonetti G. Short and long-term effects of exercise training on the tonic autonomic modulation of heart rate variability after myocardial infarction. Eur Heart J 1996;17:532-8.
84. Mazzuero G, Lanfranchi P, Colombo, Giannuzzi P, Giordano A. Long-term adaptation of 24-hour heart rate variability after myocardial infarction. The EAMI study group. Exercise training in anterior myocardial infarction. Chest 1992;101:304S-8S.
85. Anda RF, Williamson DF, Escobedo LG, Mast EE, Giovino GA, Remington PL. Depression and the dynamics of smoking: a national perspective. JAMA 1990;264:1541-5.
86. Breslau N, Kilbey MM, Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. Am J Psychiatry 1992;149:464-9.
87. Blumenthal JA, Williams RS, Wallace AG, Williams RB, Needles TL. Physiological and psychological variables predict compliance to prescribed exercise therapy in patients recovering from myocardial infarction. Psychosom Med 1882;44:519-27.
88. Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, Marzec U, Harker LA, Nemeroff CB. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996;53: 1313-7.
89. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and β-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997;42:290-5.
90. Flores NA, Sheridan DJ. The pathophysiological role of platelets during myocardial ischemia. Cardiovasc Res 1994;28:295-302.
91. Alderman CP, Moritz CK, Ben-Tovim DU. Abnormal platelet aggregation associated with fluoxetine therapy. Ann Pharmacother 1992;26:1517-9.
92. Humphries JE, Wheby MS, VandenBerg SR. Fluoxetine and the bleeding time. Arch Pathol Lab Med 1990;114:727-8.
93. Finkel M, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996;32:653-8.
94. Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature 1983;305: 627-30.
95. Hare JM, Keaney JF, Balligand JL, Loscalzo J, Smith TW, Colucci WS. Role of nitric oxide in parasympathetic modulation of β adrenergic myocardial contractility in normal dogs. J Clin Invest 1995;95:360-6.
96. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium derived relaxing factor (EDRF). Nature 1987;327:524-5.
97. Stein PE, Carney RM, Freedland KE, Skala JA, Kleiger RE, Rottman JN, Jaffe AS. Severe depression is associated with markedly reduced heart rate variability in patients with stable coronary heart disease. J Psychosom Res. In press 1999.